contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    pageUrl
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
  ... on Webcast {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


diamyd-medical-ab-diamyd-medical-meddelar-att-niklas-axelsson-beslutat-att-lamna-sin-tjanst-som-cfo-for-att-anta-en-ny-roll-i-ett-annat-foretag

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Diamyd Medical is active in diabetes research. The company has developed a vaccine that contains the active ingredient and molecule GAD, a substance that has the potential to be an important part of the prevention of diabetes treatments in the future. The company has operations on a global level with the largest presence in the Nordic region. The headquarters are located in Stockholm.

The negative reaction back then was likely also related to the fact that there was no plan for the next move. It was simply stated that Ulf was drawing up a list of different options. Anders is unlikely to remain CEO for long, given his respectable age. Well, at least the Umeå plant now has a GMP certificate; surely this has some value/benefit. We’ll have to see what happens next—whether they take on a new drug candidate, an acquisition, or something else.

Whew, should I still be burning money on diabetes and biotech? Maybe the opportunity needs to be investigated more thoroughly over time. Currently, Nextcell covers my risk tolerance. @Bimmer This was not well received. Anders is a veteran and the father of the company, but his role is surely temporary. Is Anders packaging the company for sale as a service laboratory, or is he just acting as an interim CEO after Ulf’s sudden departure? Anders did step aside previously due to health issues. I haven’t followed the outfit since the results. Is there any hope for the future other than as a service provider for other companies? There is a reasonable amount of cash in the coffers but no business operations, and continuing the old drug pipelines seems like a pretty desperate endeavor. Things might only progress through an acquisition, perhaps by using the cash reserves to buy out an early-stage company to be developed in-house. Since they do have the lab space.

Great find! If you’re up for it, this might be the place for a new thread—just remember to tag it as comprehensively as possible, otherwise the thread might not be found. Regardless, the drug seems to be quite far along already, and there seems to be a market for it.

Ulf stepped down from the CEO role after ten years. He was replaced by Diamyd founder, chairman of the board, and former CEO, Anders Essen-Möller. Anders is already a respectable 85 years old and founded Diamyd when his daughter fell ill with type 1 diabetes. A recent interview about future plans can be found at this link: https://www.youtube.com/live/54jiO5MScew?si=CKpceovrfix45puZ

To all you investors who believed in diabetes treatment drugs and lost your money in Diamyd, I recommend turning your gaze to a company called Nektar - $NKTR. They have a very interesting diabetes trial underway with a drug that targets Tregs, aiming to restore the body’s own immune regulation to balance. The drug has already shown very promising signs in phase 2b trials for other autoimmune diseases such as Atopic Dermatitis and Alopecia. Although the market cap is higher than Diamyd’s was when people were betting on it, the potential market size for Nektar is significantly larger.

There’s no point in selling in this bankruptcy. It still amazes me how the difference can be so radical compared to previous data that it’s not even worth continuing the study to the end. The probability that previous positive results were just a coincidence is quite small, isn’t it?

Good to know, the expenses stop running and they can do the trial’s autopsy. I’ll hold the earthly remains of the position out of academic interest.

Diamyd Medical

En översyn för att finna en efterträdare inleds nu och Niklas kommer finnas kvar i bolaget under en tid framöver för att möjliggöra en överlämning till denne."Trots att Niklas har arbetat fö...

En översyn för att finna en efterträdare inleds nu och Niklas kommer finnas kvar i bolaget under en tid framöver för att möjliggöra en överlämning till denne."Trots att Niklas har arbetat för Diamyd under en relativt kort period har han satt avtryck i organisationen. Jag vill framföra tacksamhet från bolagets sida - framförallt gällande den del han spelat i vår senaste kapitalanskaffning - och önskar honom lycka till med sin fortsatta karriär", säger Anders Essen-Möller, vd för Diamyd Medical. Om Diamyd Medical Diamyd Medical är ett svenskt bioteknikföretag med fokus på precisionsmedicinska behandlingar för typ 1-diabetes och biologisk tillverkning. Bolagets prövningsläkemedel retogatein, baserat på rekombinant GAD65, utvärderades i fas 3-studien DIAGNODE-3 för nydebuterad typ 1-diabetes. Bolaget har etablerat en anläggning för tillverkning av biologiska produkter i Umeå, Sverige. Diamyd Medicals B-aktie handlas på Nasdaq First North Growth Market under kortnamnet DMYD B. FNCA Sweden AB är bolagets Certified Adviser.<div></div>

Diamyd Medical AB: Diamyd Medical meddelar att Niklas Axelsson beslutat att lämna sin tjänst som CFO för att anta en ny roll i ett annat företag

Diamyd Medical AB: Diamyd Medical meddelar att Niklas Axelsson beslutat att lämna sin tjänst som CFO för att anta en ny roll i ett annat företag